3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
31
Terminated
10
Unknown
5
Withdrawn
2
Active not recruiting
2
Recruiting
1
No longer available
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
170
Rituximab
143
Specimen Handling
82
venetoclax
79
fludarabine
78
Vincristine
69
obinutuzumab
67
Doxorubicin
66
Prednisone
65
Biopsy
64
Magnetic Resonance Spectroscopy
62
zanubrutinib
52
Lenalidomide
52
Dexamethasone
49
Methotrexate
43
Cytarabine
43
blinatumomab
40
acalabrutinib
37
Immunotherapy, Adoptive
37
Bendamustine Hydrochloride
37
Etoposide
32
fludarabine phosphate
31
ibrutinib
28
glofitamab
28
polatuzumab vedotin
26
pirtobrutinib
24
orelabrutinib
24
Gemcitabine
23
Injections
21
Mercaptopurine
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
plerixafor
×
Lymphoid
×
Clear all
NCT07188090
2025-11-28
HSCT
Thomas Jefferson University
Phase 2
Recruiting
100 enrolled